QC
OVID icon

Quadrature Capital’s Ovid Therapeutics OVID Stock Holding History

Quadrature Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Buy
111,804
+23,930
+27% +$42.8K ﹤0.01% 1046
2025
Q4 		$143K Buy
87,874
+60,171
+217% +$92.7K ﹤0.01% 1038
2025
Q3 		$35.9K Buy
+27,703
New +$24K ﹤0.01% 972

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Quadrature Capital's OVID Position: Q1 2026 in Review

Quadrature Capital increased its Ovid Therapeutics (OVID) stake by 27% in Q1 2026, buying an estimated $42.8K and bringing the position to 111,804 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #1046.

Quadrature Capital first reported a position in OVID in Q3 2025 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Quadrature Capital held 111,804 shares of Ovid Therapeutics worth $248K as of Q1 2026.
  • Quadrature Capital bought 23,930 Ovid Therapeutics shares in Q1 2026, an estimated $42.8K.
  • Ovid Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1046 holding.
  • Quadrature Capital first reported a position in Ovid Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.